Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride

Journal of Liposome Research

Volumn 24, Issue 4, 2014, Pages 323-335

  Corace, Giuseppe ^a   Angeloni, Cristina ^a   Malaguti, Marco ^a   Hrelia, Silvana ^a   Stein, Paul C ^b   Brandl, Martin ^b   Gotti, Roberto ^a   Luppi, Barbara ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antioxidant activity; Enhanced permeation; Nasal administration; Neuronal uptake

Indexed keywords

ALPHA TOCOPHEROL; CHOLESTEROL; EXCIPIENT; LIPOSOME; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; REACTIVE OXYGEN METABOLITE; TACRINE; CHOLINESTERASE INHIBITOR; DRUG CARRIER; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSYNTHESIS; CELL PROTECTION; CELL VIABILITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PENETRATION; DRUG SYNTHESIS; DRUG UPTAKE; ENCAPSULATION; EVAPORATION; HUMAN; HUMAN CELL; MEMBRANE FILTER EXTRUSION; MEMBRANE FUSION; MEMBRANE PERMEABILITY; MUCOADHESION; NERVE CELL; NEUROPROTECTION; NONHUMAN; NOSE MUCOSA; OXIDATIVE STRESS; PARTICLE SIZE; REVERSE PHASE EVAPORATION; ZETA POTENTIAL; ADHESION; ANIMAL; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DOMESTIC SHEEP; DRUG EFFECTS; IN VITRO STUDY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ADHESIVENESS; ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLINESTERASE INHIBITORS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; IN VITRO TECHNIQUES; LIPOSOMES; MEMBRANE FUSION; NASAL MUCOSA; NEURONS; NOOTROPIC AGENTS; OXIDATIVE STRESS; SHEEP, DOMESTIC; TACRINE;

EID: 84911492517     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2014.899369     Document Type: Article

References (55)

1. Angeloni C, Leoncini E, Malaguti M, et al. (2009). Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J Agric Food Chem 57:5615-22.
2. 2 preconditioning modulates phase II enzymes through p38 MAPK and PI3K/Akt activation. Am J Physiol Heart Circ Physiol 300:2196-205.
3. Bellott R, Auvrignon A, Leblanc T, et al. (2001). Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 47:15-21.
4. Cerchiara T, Luppi B, Chidichimo G, et al. (2005). Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems. Eur J Pharm Biopharm 61:195-200.
5. Cohen Y, Weitman H, Afri M, et al. (2012). The effect of intercalants on the host liposome. J Liposome Res 22:306-18.
6. Cortesi R, Esposito E, Gambarin S, et al. (1999). Preparation of liposomes by reverse-phase evaporation using alternative organic solvents. J Microencapsul 16:251-6.
7. Dae-Duk K. (2007). In vitro cellular models for nasal drug absorption studies. In: Carsten E, Kwang-Jin K, eds. Drug absorption studies: in situ, in vitro and in silico models. USA: Springer, 216-34.
8. Davis KL, Powchik P. (1995). Tacrine. Lancet 345:625-30.
9. Di Cagno M, Luppi B. (2013). Drug "supersaturation" states induced by polymeric micelles and liposomes: a mechanistic investigation into permeability enhancements. Eur J Pharm Sci 48:775-80.
10. Dogterom P, Nagelkerke JF, Mulder GJ. (1988). Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of Glutathione and Vitamin E. Biochem Pharmacol 7:2311-13.
11. Edison B. (2009). Analysis of tocopherols by high performance liquid chromatography. E-J Chem 6:395-8.
12. Fischer SM, Flaten GE, Hagesæther E, et al. (2011). In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. J Pharm Pharmacol 63:1022-30.
13. Flaten GE, Dhanikula AB, Luthman K, Brandl M. (2006). Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion. Eur J Pharm Sci 27:80-90.
14. Gallarate M, Chirio D, Trotta M, Carlotti E. (2006). Deformable liposomes as topical formulations containing α-tocopherol. J Dispers Sci Technol 27:703-13.
15. Gavini E, Rassu G, Sanna V, et al. (2005). Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol 57:287-94.
16. Gervais FG, Xu D, Robertson GS, et al. (1999). Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97:395-406.
17. Giacobini E. (1993). Pharmacotherapy of Alzheimer's disease: new drugs and novel therapy. In: Corain B, Iqbal K, Nicolini M, et al, eds, Alzheimer's disease: advances in clinical and basic research. New York: Wiley, 529-38.
18. Grohganz H, Ziroli V, Massing U, Brandl M. (2003). Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS PharmSciTech 4:E63.
19. Guglielmotto M, Gilberto L, Tamagno E, Tabaton M. (2010). Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci 2:1-8.
20. Hamed AS, Azza AM, Amany OK, et al. (2012). Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 22:336-45.
21. Hartvig P, Askmark H, Aquilonius SM, et al. (1990). Clinical pharmacokinetics of intravenous and oral 9-amino-l,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 38:259-63.
22. Hossain Z, Kurihara H, Hosokawa M, Takahashi K. (2006). Docosahexaenoic acid and eicosapentaenoic acid-enriched phosphatidylcholine liposomes enhance the permeability, transportation and uptake of phospholipids in Caco-2 cells. Mol Cell Biochem 285:155-63.
23. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1-18.
24. Illum L. (2012). Nasal drug delivery - recent developments and future prospects. J Control Release 161:254-63.
25. Ivanov IT. (2001). Rapid method for comparing the cytotoxicity of organic solvents and their ability to destabilize proteins of the erythrocytemembrane. Pharmazie 56:808-9.
26. Jaafari MR, Tafaghodi M, Abolghassem S, Tabassi S. (2005). Evaluation of the clearance characteristics of liposomes in the human nose by gamma-scintigraphy. Iran J Pharm Res 1:3-11.
27. Jogani VV, Shah PJ, Mishra P, et al. (2007). Nose-to-brain delivery of tacrine. J Pharm Pharmacol 59:1199-205.
28. Kagan VE, Bakalova RA, Zhelev Z, et al. (1990). Intermembrane transfer and antioxidant action of α-tocopherol in liposomes. Arch Biochem Biophys 280:147-52.
29. Law SL, Huang KJ, Chou VHY, Cherng JY. (2001) Enhancement of nasal absorption of calcitonin loaded liposomes. J Liposome Res 11:165-74.
30. Leo A, Hansch C, Elkins D. (1971). Partition coefficients and their uses. Chem Rev 71:525-616.
31. Luppi B, Bigucci F, Cerchiara T, et al. (2008). New environmental sensitive system for colon-specific delivery of peptidic drugs. Int J Pharm 358:44-9.
32. Luppi B, Bigucci F, Abruzzo A, et al. (2010). Freeze-dried chitosan/pectin nasal inserts for antipsychotic drug delivery. Eur J Pharm Biopharm 75:381-7.
33. Luppi B, Bigucci F, Corace G, et al. (2011). Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559-65.
34. Masaki KH, Losonczy KG, Izmirlian G, et al. (2000). Association of vitamins E and C supplement use with cognitive function and dementia in elderly men. Neurology 54:1265-72.
35. Masliah E, Mallory M, Alford M, et al. (1998). Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 57:1041-52.
36. Mathison S, Nagilla R, Kompella UB. (1998). Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target 5:415-41.
37. Minarini A, Milelli A, Tumiatti V, et al. (2012). Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. Neuropharmacology 62:997-1003.
38. Nakagawa H, Shiina T, Sekino M, et al. (2007). Fusion and molecular aspects of liposomal nanocarriers incorporated with isoprenoids. IEEE Trans Nanobioscience 6:219-22.
39. Nii T, Ishii F. (2005). Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharm 298:198-205.
40. Pidgeon C, McNeely S, Schmidt T, Johnson JE. (1987). Multilayered vesicles prepared by reverse-phase evaporation: liposome structure and optimum solute entrapment. Biochemistry 26:17-29.
41. Polinsky RJ. (1998). Clinical pharmacology of rivastigmine: a new generation acetyl choline esterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20:634-7.
42. Quinn PJ. (2012). The effect of tocopherol on the structure and permeability of phosphatidylcholine liposomes. J Control Release 160:58-63.
43. Rasti B, Jinap S, Mozafari MR, Abd-Manap MY. (2013). Optimization on preparation condition of polyunsaturated fatty acids nanoliposome prepared by Mozafari method. J Liposome Res. [Epub ahead of print]. doi:10.3109/08982104.2013.839702.
44. Rovoli M, Gortzi O, Lalas S, Kontopidis G. (2014). β-Lactoglobulin improves liposome's encapsulation properties for vitamin E delivery. J Liposome Res 24:74-81.
45. Stein PC, di Cagno MP, Bauer-Brandl A. (2011). A novel method for the investigation of liquid/liquid distribution coefficients and interface permeabilities applied to the water-octanol-drug system. Pharm Res 28:2140-6.
46. Stone WL, Mukherjee S, Smith M, Das SK. (2002). Therapeutic uses of antioxidant liposomes. Methods Mol Biol 199:145-61.
47. Summers WK. (2006). Tacrine, and Alzheimer's treatments. J Alzheimers Dis 9:439-45.
48. Szoka Jr F, Papahadjopoulos D. (1978). Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75:4194-8.
49. Tarozzi A, Morroni F, Merlicco A, et al. (2009). Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line. J Neurochem 111:1161-71.
50. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. (2005). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-96.
51. Uetsuki T, Takemoto K, Nishimura I, et al. (1999). Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein. J Neurosci 19:6955-64.
52. Vemuri S, Rhodes CT. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 70:95-111.
53. Wagstaff AJ, McTavish D. (1994). Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 4:510-54.
54. Westin U, Piras E, Jansson B, et al. (2005). Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 24:565-73.
55. Yazawa K. (1996). DHA supplementation in dementia. Presented at international Society for the study of Fatty Acids and Lipids, Barcelona, Spain.